High-dose chemotherapy with subsequent autologous stem cell transplantation is believed to be of therapeutic benefit in patients with acute myeloid leukemia (AML), especially when no allogeneic bone marrow donor is available. One of the main risks is contamination of the stem cell preparations with leukemic blasts, which may account for a higher relapse rate compared to allogeneic bone marrow transplantation. Since overexpression of WT1 is common in leukemic blasts, we investigated, whether PBSCs from AML patients express WT1 at a higher level as compared to patients with solid cancers. PBSCs of seven patients with AML and of five patients with solid cancers were investigated for WT1 expression. Total WT1 copy count was determined in a standardized quantitative real time RT-PCR. WT1 expression was found in all AML PBSCs with an average copy number of 49.99 ؎ 61.09. In solid cancers WT1 expression was statistically significantly lower with a copy number of 3.51 ؎ 1.92. In AML patients with sustained complete remission we found a nearly significantly lower WT1 expression than in patients who relapsed within the first year after stem cell transplantation. Our data show a higher WT1 expression in PBSCs of AML patients compared to patients with solid cancers. This finding might indicate a contamination with leukemic blasts. Quantification of WT1 in PBSCs might therefore be useful to estimate the risk of relapse after autologous stem cell transplantation in AML patients.
The Wilms tumor gene (WT1) encodes a zinc-finger transcription factor that plays an important role in controlling cellular growth and differentiation. 1 During embryogenesis, WT1 is transiently expressed in various tissues, including the hematopoietic cell system. 2 In adult hematopoiesis, transient WT1 expression characterizes immature CD34 ϩ precursor cells. 3 Upon deregulation, WT1 is possibly leukemogenic. 4 Blasts of the majority of acute myeloid and lymphoid leukemia patients express WT1, whereas patients with reactive changes to their bone marrow due to infections or malignancies show no significant WT1 expression. 5, 6 WT1 expression is not detectable in patients with leukemic low-grade non-Hodgkin's lymphoma (NHL) or in patients with chronic myeloid leukemia in chronic phase. Stem cell preparations of solid cancer patients express WT1 at low levels, if at all. 7 Taken together, WT1 expression is a possible marker for minimal residual disease in acute leukemia patients. However, controlled pre-PCR conditions of the mononuclear cell (MNC) samples are highly important for accurate and reliable measurements of WT1 expression using quantitative RT-PCR protocols.
Studies by the German AML Cooperative Group (AMLCG) are in process to evaluate high-dose chemotherapy with subsequent autologous blood stem cell support for the treatment of de novo AML patients. Contaminating leukemic blasts in PBSCs possibly accounting for a higher relapse rate compared to allogeneic stem cell transplantation remain the primary obstacle to this approach. Further, detection of leukemic blasts in PBSCs indicates an unfavorable remission quality. To assess for contamination with leukemic blasts, we analyzed unpurged and immunopurged PBSCs from AML and solid cancer patients (negative controls) for WT1 expression, using a completely standardized real-time WT1-RT-PCR protocol (TaqMan).
Materials and methods
Total mRNA of 10 6 MNCs obtained from PBSCs of AML patients (n ϭ 7), who received autologous PBSC in our department during the last 2 years was isolated (Rneasy; Qiagen, Hilden, Germany) and transcribed into cDNA (M- MLV, Life Tech., Karlsruhe, Germany). In five patients purged and unpurged PBSCs were available, which were analyzed separately. Purged PBSCs were prepared using immunomagnetic beads coupled with CD34 ϩ -binding antibodies (CliniMACS; Miltenyi Biotec, Bergisch Gladbach, Germany). As controls, PBSCs from randomly selected patients (n ϭ 5) who received autologous stem cell support for solid cancer treatment were processed. Finally, three successive PBSCs of a heavily pretreated high-grade NHL patient with initial bone marrow involvement were analyzed. This patient developed secondary AML-M4 2 years after receiving PBSC support. Real-time quantitative WT1-RT-PCR was performed on a GeneAmp 5700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) using TaqMan technology (forward primer: 5ЈCGCTATTCGCAATCAGGGTTAC; reverse primer: 5ЈATGGGATCCT-CATGCTTGAATG; TaqMan-Probe: 5ЈFAM-CGGTCACCTTCGACGGGACGC-TAMRA; 40 cycles with 2 min 50°C; 10 min, 95°C; 15 s 95°C; 1 min 60°C; amplicon length 119 bp). Six reactions were performed with each probe. A dilution series of WT1 copies amplified in pBluescript II KSϩ (Stratagene, La Jolla, CA, USA) with an inserted 143 bp fragment from exon 1-2 of the WT1 gene (pBWTT) was used as reference control. The number of amplified WT1 copies in the dilution series and probes was calculated using GeneAmp 5700 SDS Software.
As an internal standard GAPDH cDNA was also measured in the same way as WT1. Six MNC samples from every PBSC preparation were measured simultaneously, and these measurements were averaged. Also, WT1 copy numbers from PBSCs of a single patient which were obtained successively over 2 or 3 days, were averaged.
Results
An excellent correlation of 0.99 was found in the range from 10 1 to 10 6 copies of WT1 cDNA between the measurements (n ϭ 6) of pBWTT standard serial dilutions. Expression of WT1 was found in all PBSCs of AML patients (n ϭ 7) with an average copy number of 49.99 Ϯ 61.09 (Table 1 ). In purged AML PBSCs the WT1 copy number was stable up to two-fold higher ( Table 1 ). The five PBSCs of the solid cancer patients showed a substantially lower WT1 expression level. For these controls, the average WT1 copy number was 3.51 Ϯ 1.92 (Table 1) . The difference in WT1 copy numbers between AML and solid cancer patients was statistically significant (P ϭ 0.021; Mann-Whitney test). Further, WT1 copy numbers of PBSCs from AML patients with sustained complete remission (n ϭ 3) were almost significantly lower as compared to those from AML patients who relapsed within the first year after autologous PBSC support (n ϭ 4; P ϭ 0.054; Mann-Whitney test). High WT1 copy numbers were found in all three PBSCs from a high-grade NHL patient who successively developed secondary AML-M4 (26, 62, and 85 WT1 copies, respectively).
Discussion
We conclude that PBSCs from AML patients have a significantly higher WT1 expression level as compared to those obtained from solid cancer patients. This finding most likely indicates the presence of contaminating leukemic blasts in PBSCs of AML patients. In PBSCs from AML patients who relapsed within 12 months after PBSC support, a substantially higher WT1 copy number was found as compared to AML patients in sustained complete remission. However, this difference indicates a trend only and was not significant at the 5% level. Based on our findings, a multicenter trial should be initiated to define a WT1 expression threshold level indicative for AML patients who will possibly benefit from autologous PBSC support as compared to others, using a completely standardized realtime WT1-RT-PCR protocol. In certain patients at high risk to develop secondary AML such as heavily pretreated lymphoma patients, quantitative testing for WT1 expression might be useful to identify the evolution of acute leukemia months prior to hematological and clinical signs of this disease.
